Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Intellia Therapeutics, Inc.NTLA · Entity 4585 | EVP, Chief Financial Officer | March 01, 2024 | March 05, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Intellia Therapeutics, Inc.
Report date March 01, 2024 · Filed March 05, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 69,213 |
Reported balance
After 2024-03-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-03-01 · Grant · Acquired 28,628 · Balance 69,213 F1: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.66 · Expires 2034-02-28 | Direct | 41,316 |
Reported balance
After 2024-03-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-03-01 · Grant · Acquired 41,316 · Balance 41,316 F2: This option was granted on March 1, 2024 with respect to shares of Common Stock, with 33% vesting on January 1, 2025 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
F2: This option was granted on March 1, 2024 with respect to shares of Common Stock, with 33% vesting on January 1, 2025 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2024 Filed Mar 5, 2024 21:10 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 41,316 | $0.00 Strike: $32.66 | $0.00 |
DisclosureSEC source: 0000950170-24-025901 · ownership.xml · derivative · entry 2 Goddard Glenn · CIK 0001581992 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,316 Underlying: Common Stock · 41,316 shares Expires 2034-02-28 F2 · derivative.exercise_date: This option was granted on March 1, 2024 with respect to shares of Common Stock, with 33% vesting on January 1, 2025 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:10 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 28,628 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-025901 · ownership.xml · nonDerivative · entry 1 Goddard Glenn · CIK 0001581992 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,213 F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 21:49 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 5,365 | $29.46 | $158,052.90 |
DisclosureSEC source: 0000950170-24-002511 · ownership.xml · nonDerivative · entry 1 Goddard Glenn · CIK 0001581992 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,585 F1 · kind: Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2024, and does not represent a volitional trade by the Reporting Person. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 22:28 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionRestricted Stock Unit · Derivative | 3,062 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-001173 · ownership.xml · derivative · entry 2 Goddard Glenn · CIK 0001581992 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,064 Underlying: Common Stock · 3,062 shares Expires 2031-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On March 3, 2021, the reporting person was granted 12,250 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 22:28 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionCommon Stock | 3,062 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-001173 · ownership.xml · nonDerivative · entry 1 Goddard Glenn · CIK 0001581992 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,950 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 22:20 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 38,834 | $0.00 Strike: $40.75 | $0.00 |
DisclosureSEC source: 0001209191-23-015776 · doc4.xml · derivative · entry 2 Goddard Glenn · CIK 0001581992 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,834 Underlying: Common Stock · 38,834 shares Expires 2033-02-28 F2 · derivative.exercise_date: This option was granted on March 1, 2023 with respect to shares of Common Stock, with 33% vesting on January 1, 2024 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 22:20 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 27,484 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-015776 · doc4.xml · nonDerivative · entry 1 Goddard Glenn · CIK 0001581992 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,888 F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 22:23 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 2,427 | $37.21 | $90,308.67 |
DisclosureSEC source: 0001209191-23-002414 · doc4.xml · nonDerivative · entry 1 Goddard Glenn · CIK 0001581992 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,404 F1 · kind: Shares sold in sell-to-cover transaction in order to satisfy withholding taxes to be paid upon the vesting of RSUs on January 1, 2023. Read SEC document |
| January 01, 2023 Filed Jan 5, 2023 01:29 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionRestricted Stock Unit · Derivative | 3,062 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-001490 · doc4.xml · derivative · entry 2 Goddard Glenn · CIK 0001581992 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,126 Underlying: Common Stock · 3,062 shares Expires 2031-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On March 3, 2021, the reporting person was granted 12,250 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter. F2 · derivative.expiration_date: On March 3, 2021, the reporting person was granted 12,250 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter. Read SEC document |
| January 01, 2023 Filed Jan 5, 2023 01:29 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionCommon Stock | 3,062 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-001490 · doc4.xml · nonDerivative · entry 1 Goddard Glenn · CIK 0001581992 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,831 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 00:38 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 12,720 | $0.00 Strike: $79.85 | $0.00 |
DisclosureSEC source: 0001209191-22-015917 · doc4.xml · derivative · entry 5 Goddard Glenn · CIK 0001581992 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,720 Underlying: Common Stock · 12,720 shares Expires 2032-02-28 F5 · derivative.exercise_date: This option was granted on March 1, 2022 with respect to shares of Common Stock, with 33% vesting on January 1, 2023 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 00:38 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 12,720 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-015917 · doc4.xml · nonDerivative · entry 3 Goddard Glenn · CIK 0001581992 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,769 F3 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Read SEC document |
| March 01, 2022 Filed Mar 5, 2022 02:04 UTC Amendment | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 18,600 | $0.00 Strike: $79.85 | $0.00 |
DisclosureSEC source: 0001209191-22-016535 · doc4a.xml · derivative · entry 1 Goddard Glenn · CIK 0001581992 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,600 Underlying: Common Stock · 18,600 shares Expires 2032-02-28 F1 · shares: The original Form 4 incorrectly reported the number of options granted as 12,720. F2 · derivative.exercise_date: This option was granted on March 1, 2022 with respect to shares of Common Stock, with 33% vesting on January 1, 2023 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter. F1 · derivative.underlying_shares: The original Form 4 incorrectly reported the number of options granted as 12,720. F1 · balance_after: The original Form 4 incorrectly reported the number of options granted as 12,720. Read SEC document |
| January 01, 2022 Filed Mar 4, 2022 00:38 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionRestricted Stock Unit · Derivative | 3,062 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-015917 · doc4.xml · derivative · entry 4 Goddard Glenn · CIK 0001581992 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,188 Underlying: Common Stock · 3,062 shares Expires 2031-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: On March 3, 2021, the reporting person was granted 12,250 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter. F4 · derivative.expiration_date: On March 3, 2021, the reporting person was granted 12,250 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter. Read SEC document |
| January 01, 2022 Filed Mar 4, 2022 00:38 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 1,013 | $112.24 | $113,699.12 |
DisclosureSEC source: 0001209191-22-015917 · doc4.xml · nonDerivative · entry 2 Goddard Glenn · CIK 0001581992 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,049 F2 · kind: Shares sold in sell-to-cover transaction in order to satisfy withholding taxes to be paid upon the vesting of RSUs on January 1, 2022. Read SEC document |
| January 01, 2022 Filed Mar 4, 2022 00:38 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionCommon Stock | 3,062 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-015917 · doc4.xml · nonDerivative · entry 1 Goddard Glenn · CIK 0001581992 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,062 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 21:38 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionStock Option (right to buy) · Derivative | 3,482 | $0.00 Strike: $14.58 | $0.00 |
DisclosureSEC source: 0001209191-21-055347 · doc4.xml · derivative · entry 3 Goddard Glenn · CIK 0001581992 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,451 Underlying: Common Stock · 3,482 shares Expires 2028-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 11,833 shares as of September 7, 2021. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 21:38 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 3,482 | $180.12 | $627,177.84 |
DisclosureSEC source: 0001209191-21-055347 · doc4.xml · nonDerivative · entry 2 Goddard Glenn · CIK 0001581992 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $180.00 to $180.50, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 7, 2021 at each separate price. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 21:38 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionCommon Stock | 3,482 | $14.58 | $50,767.56 |
DisclosureSEC source: 0001209191-21-055347 · doc4.xml · nonDerivative · entry 1 Goddard Glenn · CIK 0001581992 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,482 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2021 Filed Sep 1, 2021 23:30 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionStock Option (right to buy) · Derivative | 1,817 | $0.00 Strike: $14.58 | $0.00 |
DisclosureSEC source: 0001209191-21-054315 · doc4.xml · derivative · entry 15 Goddard Glenn · CIK 0001581992 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,933 Underlying: Common Stock · 1,817 shares Expires 2028-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F13 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 11,833 shares as of August 31, 2021. Read SEC document |
| August 31, 2021 Filed Sep 1, 2021 23:30 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionStock Option (right to buy) · Derivative | 22,983 | $0.00 Strike: $19.27 | $0.00 |
DisclosureSEC source: 0001209191-21-054315 · doc4.xml · derivative · entry 14 Goddard Glenn · CIK 0001581992 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,817 Underlying: Common Stock · 22,983 shares Expires 2028-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 63,750 shares as of August 31, 2021. Read SEC document |
| August 31, 2021 Filed Sep 1, 2021 23:30 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 24,800 | $160.22 | $3,973,456.00 |
DisclosureSEC source: 0001209191-21-054315 · doc4.xml · nonDerivative · entry 12 Goddard Glenn · CIK 0001581992 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $160.00 to $160.59, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 31, 2021 at each separate price. Read SEC document |
| August 31, 2021 Filed Sep 1, 2021 23:30 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionCommon Stock | 1,817 | $14.58 | $26,491.86 |
DisclosureSEC source: 0001209191-21-054315 · doc4.xml · nonDerivative · entry 11 Goddard Glenn · CIK 0001581992 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2021 Filed Sep 1, 2021 23:30 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionCommon Stock | 22,983 | $19.27 | $442,882.41 |
DisclosureSEC source: 0001209191-21-054315 · doc4.xml · nonDerivative · entry 10 Goddard Glenn · CIK 0001581992 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,983 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 30, 2021 Filed Sep 1, 2021 23:30 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionStock Option (right to buy) · Derivative | 5,200 | $0.00 Strike: $19.27 | $0.00 |
DisclosureSEC source: 0001209191-21-054315 · doc4.xml · derivative · entry 13 Goddard Glenn · CIK 0001581992 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,800 Underlying: Common Stock · 5,200 shares Expires 2028-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 63,750 shares as of August 30, 2021. Read SEC document |
| August 30, 2021 Filed Sep 1, 2021 23:30 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 300 | $160.84 | $48,252.00 |
DisclosureSEC source: 0001209191-21-054315 · doc4.xml · nonDerivative · entry 9 Goddard Glenn · CIK 0001581992 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $160.61 to $160.95, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price. Read SEC document |
| August 30, 2021 Filed Sep 1, 2021 23:30 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 300 | $159.53 | $47,859.00 |
DisclosureSEC source: 0001209191-21-054315 · doc4.xml · nonDerivative · entry 8 Goddard Glenn · CIK 0001581992 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $159.31 to $159.79, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price. Read SEC document |
| August 30, 2021 Filed Sep 1, 2021 23:30 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 300 | $158.42 | $47,526.00 |
DisclosureSEC source: 0001209191-21-054315 · doc4.xml · nonDerivative · entry 7 Goddard Glenn · CIK 0001581992 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.08 to $158.81, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price. Read SEC document |
| August 30, 2021 Filed Sep 1, 2021 23:30 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 496 | $157.33 | $78,035.68 |
DisclosureSEC source: 0001209191-21-054315 · doc4.xml · nonDerivative · entry 6 Goddard Glenn · CIK 0001581992 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 900 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $156.86 to $157.84, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price. Read SEC document |
| August 30, 2021 Filed Sep 1, 2021 23:30 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 300 | $156.10 | $46,830.00 |
DisclosureSEC source: 0001209191-21-054315 · doc4.xml · nonDerivative · entry 5 Goddard Glenn · CIK 0001581992 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,396 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $155.81 to $156.30, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price. Read SEC document |
| August 30, 2021 Filed Sep 1, 2021 23:30 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 1,700 | $155.29 | $263,993.00 |
DisclosureSEC source: 0001209191-21-054315 · doc4.xml · nonDerivative · entry 4 Goddard Glenn · CIK 0001581992 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,696 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $154.805 to $155.74, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price. Read SEC document |
| August 30, 2021 Filed Sep 1, 2021 23:30 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 1,100 | $154.29 | $169,719.00 |
DisclosureSEC source: 0001209191-21-054315 · doc4.xml · nonDerivative · entry 3 Goddard Glenn · CIK 0001581992 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,396 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $153.76 to $154.71, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price. Read SEC document |
| August 30, 2021 Filed Sep 1, 2021 23:30 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 704 | $153.22 | $107,866.88 |
DisclosureSEC source: 0001209191-21-054315 · doc4.xml · nonDerivative · entry 2 Goddard Glenn · CIK 0001581992 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,496 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.75 to $153.62, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price. Read SEC document |
| August 30, 2021 Filed Sep 1, 2021 23:30 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionCommon Stock | 5,200 | $19.27 | $100,204.00 |
DisclosureSEC source: 0001209191-21-054315 · doc4.xml · nonDerivative · entry 1 Goddard Glenn · CIK 0001581992 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 05, 2021 Filed Aug 6, 2021 22:17 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $19.27 | $0.00 |
DisclosureSEC source: 0001209191-21-050225 · doc4.xml · derivative · entry 5 Goddard Glenn · CIK 0001581992 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 20,000 shares Expires 2028-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 61,875 shares as of August 5, 2021. Read SEC document |
| August 05, 2021 Filed Aug 6, 2021 22:17 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 530 | $152.13 | $80,628.90 |
DisclosureSEC source: 0001209191-21-050225 · doc4.xml · nonDerivative · entry 4 Goddard Glenn · CIK 0001581992 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.01 to $152.38, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 5, 2021 at each separate price. Read SEC document |
| August 05, 2021 Filed Aug 6, 2021 22:17 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 9,568 | $151.41 | $1,448,690.88 |
DisclosureSEC source: 0001209191-21-050225 · doc4.xml · nonDerivative · entry 3 Goddard Glenn · CIK 0001581992 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 530 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.015 to $151.99, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 5, 2021 at each separate price. Read SEC document |
| August 05, 2021 Filed Aug 6, 2021 22:17 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 9,902 | $150.65 | $1,491,736.30 |
DisclosureSEC source: 0001209191-21-050225 · doc4.xml · nonDerivative · entry 2 Goddard Glenn · CIK 0001581992 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,098 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.01 to $151.00, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 5, 2021 at each separate price. Read SEC document |
| August 05, 2021 Filed Aug 6, 2021 22:17 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionCommon Stock | 20,000 | $19.27 | $385,400.00 |
DisclosureSEC source: 0001209191-21-050225 · doc4.xml · nonDerivative · entry 1 Goddard Glenn · CIK 0001581992 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2021 Filed Mar 5, 2021 22:49 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantRestricted Stock Unit · Derivative | 12,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-018321 · doc4.xml · derivative · entry 2 Goddard Glenn · CIK 0001581992 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,250 Underlying: Common Stock · 12,250 shares Expires not disclosed F2 · derivative.exercise_price: On March 3, 2021, the reporting person was granted 12,250 Restricted Stock Units ("RSUs") pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments. F2 · date: On March 3, 2021, the reporting person was granted 12,250 Restricted Stock Units ("RSUs") pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments. F2 · derivative.exercise_date: On March 3, 2021, the reporting person was granted 12,250 Restricted Stock Units ("RSUs") pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments. F2 · derivative.expiration_date: On March 3, 2021, the reporting person was granted 12,250 Restricted Stock Units ("RSUs") pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments. Read SEC document |
| March 03, 2021 Filed Mar 5, 2021 22:49 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 73,500 | $0.00 Strike: $57.71 | $0.00 |
DisclosureSEC source: 0001209191-21-018321 · doc4.xml · derivative · entry 1 Goddard Glenn · CIK 0001581992 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,500 Underlying: Common Stock · 73,500 shares Expires 2031-03-02 F1 · derivative.exercise_date: This option was granted on March 3, 2021 with respect to 73,500 shares of Common Stock, with 25% vesting on January 1, 2022 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 22:28 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $13.40 | $0.00 |
DisclosureSEC source: 0000899243-20-006975 · doc4.xml · derivative · entry 1 Goddard Glenn · CIK 0001581992 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2030-03-01 F1 · derivative.exercise_date: This option was granted on March 2, 2020 with respect to 125,000 shares of Common Stock, with 25% vesting on January 1, 2021 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| December 18, 2018 Filed Dec 20, 2018 21:16 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 17,750 | $0.00 Strike: $14.58 | $0.00 |
DisclosureSEC source: 0001209191-18-063657 · doc4.xml · derivative · entry 1 Goddard Glenn · CIK 0001581992 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,750 Underlying: Common Stock · 17,750 shares Expires 2028-12-17 F1 · derivative.exercise_date: This option was granted on December 18, 2018 with respect to 17,750 shares of Common Stock, with 25% vesting on December 18, 2019 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| November 01, 2018 Filed Nov 1, 2018 22:37 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $19.27 | $0.00 |
DisclosureSEC source: 0000899243-18-027919 · doc4.xml · derivative · entry 1 Goddard Glenn · CIK 0001581992 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2018-10-31 F1 · derivative.exercise_date: This option was granted on November 1, 2018 with respect to 90,000 shares of Common Stock, with 25% vesting on November 1, 2019 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| November 01, 2018 Filed Dec 20, 2018 21:15 UTC Amendment | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $19.27 | $0.00 |
DisclosureSEC source: 0000899243-18-031474 · doc4a.xml · derivative · entry 1 Goddard Glenn · CIK 0001581992 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2028-10-31 F1 · derivative.exercise_date: This option was granted on November 1, 2018 with respect to 90,000 shares of Common Stock, with 25% vesting on November 1, 2019 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.